Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-14T05:26:24.671Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-Term Use of Tianeptine in 380 Depressed Patients

Published online by Cambridge University Press:  06 August 2018

H. Lôo ,
H. Ganry ,
H. Dufour ,
J. D. Guelfi ,
R. Malka ,
J. P. Olié ,
H. Scharbach ,
J. Tignol ,
C. Marey  and
A. Kamoun
H. Lôo*
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Hôpital Sainte Anne, Paris, France
H. Ganry
Affiliation:
Institut de Recherches Internationales Servier, Courbevoie, France
H. Dufour
Affiliation:
Departement Universitaire de Psychiatrie Adulte, Hôpital de Cery, Lausanne, Switzerland
J. D. Guelfi
Affiliation:
Clinique des Maladies Mentales et de l'Encephale, Hôpital Sainte Anne, Paris, France
R. Malka
Affiliation:
Centre Gilbert Raby, Meulan, et Institut de Psychiatrie La Rochefoucault, Paris, France
J. P. Olié
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Hôpital Sainte Anne, Paris, France
H. Scharbach
Affiliation:
Centre Hospitaller Régional, Service Medico-Psychologique Infanto-Juvénile, Nantes, France
J. Tignol
Affiliation:
Centre Carreire, Bordeaux, France
C. Marey
Affiliation:
Institut de Recherches Internationales Servier, Courbevoie, France
A. Kamoun
Affiliation:
Institut de Recherches Internationales Servier, 6 place des Pléiades, 92415 Courbevoie, Cedex, France
*
Correspondence
Get access Rights & Permissions [Opens in a new window]

Extract

Tianeptine is a new tricyclic compound whose principal action is to increase the reuptake of serotonin. In a multicentre trial in which 380 depressed patients were treated for one year, tianeptine produced a significant reduction in the MADRS scores from day 14, with a sustained reduction maintained for up to 12 months; other measures of efficacy (HRSA, HSCL, and CGI) also reflected the improvement. Only 11% of patients withdrew because of recurrence of depression and 2% because of side-effects, which were mainly drowsiness, irritability, and gastrointestinal disturbance. Apart from a minor reduction in heart rate, unaccompanied by any conduction changes, no clinically relevant changes in vital signs or laboratory tests were seen. Seven subjects who attempted suicide by tianeptine overdose had favourable outcomes, in spite of also taking other psychotropic drugs or alcohol. No evidence of tolerance or withdrawal symptoms was seen after treatment was stopped. These results suggest that tianeptine has the potential to provide safe antidepressant activity in both the acute and chronic phases of treatment.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 160 , Issue S15: Stress, Serotonin and Tianeptine , February 1992 , pp. 61 - 65
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, J., Bech, P., Boyer, P., et al (1989) Consensus conference on the methodology of clinical trials of antidepressants. Report of the Consensus Committee. Pharmacopsychiatry, 22, 3–7.CrossRefGoogle Scholar
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorder (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Beaumont, G. (1988) Adverse effects of tricyclic and non-tricyclic antidepressants. In Advances in the Chemotherapy of Depression: Lofepramine (ed. Montgomery, S. A.). London: CNRS.Google Scholar
Bersani, G., Pasini, A., Brancato, T., et al (1989) Serotonina e depressione: studio multicentrico controllato tianeptina versus amitriptilina. XXXVII Congresso Nazionale della Societa Italiana di Psichiatria. Roma–6-11 febbraio 1989. (CIC Edizioni Internazionali), 1243–1249.Google Scholar
Davis, J. M. (1985) Antipsychotic drugs. In Comprehensive Textbook of Psychiatry IV (eds Kaplan, H. I. & Sadock, B. J.). Baltimore, USA: Williams and Wilkins.Google Scholar
Delalleau, B., Dulcire, C., Le Moine, P., et al (1988) Analysis of the side effects of tianeptine. Clinical Neuropharmacology, 11 (suppl. 2), S83–S89.Google ScholarPubMed
Deleuze, J. (1989) Ludiomil et prévention des rechutes dépressives. Revue du Praticien, 46, 27–30.Google Scholar
Derogatis, C. R., Lipman, R. S., Rickels, K., et al (1974) The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behavioral Science, 19, 1–15.CrossRefGoogle ScholarPubMed
Guelfi, J. D., Pull, C. B., Guelfi, C., et al (1983) La C.H.E.S.S. Utilisation dans la pathologie anxieuse et dépressive. Structure factorielle. Annales Medico Psychologiques, 141, 257–277.Google Scholar
Guelfi, J. D., Pichot, P. & Dreyfus, J. F. (1989) Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology, 22, 41–48.CrossRefGoogle ScholarPubMed
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health Education and Welfare.Google Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.CrossRefGoogle ScholarPubMed
Kato, G. & Weitsch, A. F. (1988) Neurochemical profile of tianeptine, a new antidepressant drug. Clinical Neuropharmacology, 11 (suppl. 2), S43–S50.Google ScholarPubMed
Labrid, C., Moleyre, J., Poignant, J. C., et al (1988) Structure –activity relationships of tricyclic antidepressant with special reference to tianeptine. Clinical Neuropharmacology, 11 (suppl. 2), S21–S31.Google ScholarPubMed
Lôo, H., Zarifian, E. & Kamoun, A. (1981) Place de la tianeptine parmi les antidépresseurs. In Proceedings of the Third World Congress of Biological Psychiatry, Stockholm (eds Perris, C., Struwe, G. & Jansson, B.). Amsterdam: Elsevier.Google Scholar
Lôo, H. & Olié, J. P. (1984) Problèmes liés à 1'arrět des antidépresseurs et du lithium. Thérapie, 39, 403–410.Google Scholar
Lôo, H., Hantzberg, P., Defrance, R., et al (1987a) Traitement par la tianeptine des syndromes dépressifs des toxicomanes sevrés. Appréciation de l'éfficacité et recherche de dépendance. Encéphale, 13, 295–299.Google Scholar
Lôo, H., Davy, J. P. & Zarifian, E. (1987b) Les antidépresseurs. Paris: Encyclopédic Médico-Chirurgicale (psychiatrie 37.804B7012.).Google Scholar
Lôo, H. & Deniker, P. (1988) Position of tianeptine among antidepressive chemotherapies. Clinical Neuropharmacology, 11 (suppl. 2), S97–S102.Google ScholarPubMed
Lôo, H., Malka, R., Defrance, R., et al (1988) Tianeptine and amitriptyline: controlled double blind trial in depressed alcholic patients. Neuropsychobiology, 19, 79–85.CrossRefGoogle Scholar
Malka, R. (1988) Role of drug therapies in the treatment of alcoholism: alcohol and anxiety – alcohol and depression. Clinical Neuropharmacology, 11 (suppl. 2), S69–S73.Google ScholarPubMed
Mennini, T. & Garattini, S. (1987) Effect of long term treatment with antidepressants on 3H serotonin uptake and 3H imipramine binding in rat brain. Journal of Receptors Research, 7, 1–4.Google Scholar
Mennini, T., Mocaër, E. & Garattini, S. (1987) Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedeberg's Archives of Pharmacology, 336, 478–482.CrossRefGoogle ScholarPubMed
Merikangas, K. R., Leckman, J. F., Prusoff, B. A., et al (1985) Familial transmission of depression and alcoholism. Archives of General Psychiatry, 42, 367–372.CrossRefGoogle ScholarPubMed
Mindham, R. H. S., Howland, C. & Sheperd, M. (1973) An evaluation of continuation therapy with tricyclic antidepressant in depressive illness. Psychological Medicine, 3, 5–17.CrossRefGoogle ScholarPubMed
Mocaër, E., Rettori, M. C. & Kamoun, A. (1988) Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clinical Neuropharmacology, 11 (suppl. 2), S32–S42.Google ScholarPubMed
Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382–389.CrossRefGoogle ScholarPubMed
Montgomery, S. A., Dufour, H., Brion, S., et al (1988) The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry, 153 (suppl. 3), 69–75.CrossRefGoogle Scholar
Ostaptzeff, G. (1981) Etude contrôlée à double insu versus imipramine de l'efficacité de la tianeptine dans les états dépressifs non psychotiques. In Proceedings of the Third World Congress of Biological Psychiatry, Stockholm in Proceedings of the Third World Congress of Biological Psychiatry, Stockholm (eds Perris, C., Struwe, G., Jansson, B.). Amsterdam: Elsevier.Google Scholar
Pellet, J., Decrat, M., Lang, F., et al (1987) Description d'un échantillon de 300 échelles MADRS portant sur des sujets déprimés. Annales Médico-Psychologiques, 145, 170–175.Google Scholar
Royer, R. J. Albin, H., Barrucand, D., et al (1988) Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clinical Neuropharmacology, 11 (suppl. 2), S90–S96.Google ScholarPubMed
Stein, M. K., Rickels, K. & Weise, C. (1980) Maintenance therapy with amitriptyline, a controlled trial. American Journal of Psychiatry, 137, 370–371.Google ScholarPubMed
Weiss, C., Gorceix, A., Kindynis, S., et al (1981) Etude contrôlée à double insu versus nomifensine de l'activité et du délai d'action d'un nouvel antidépresseur: la tianeptine. In Proceedings of the Third World Congress of Biological Psychiatry, Stockholm in Proceedings of the Third World Congress of Biological Psychiatry, Stockholm (eds Perris, C., Struwe, G., Jansson, B.). Amsterdam: Elsevier.Google Scholar
Winokur, G. (1979) Alcoholism and depression in the same family. In Alcoholism and Affective Disorders: Clinical, Genetic, and Biochemical Studies (eds Goodwin, D. W. & Erikson, P.). New York: SP Medical and Scientific Books.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.